A first-in-human trial of PRT12396 starts next month.
ApexOnco Front Page
Recent articles
Early data are coming with the KRAS G12D degrader ARV-806.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
Circle Pharma and Verismo feature in coveted sessions.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Talapro-3 could help move Talzenna into earlier prostate cancer.
